Concepedia

Publication | Open Access

Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib

DOIFull Paper Access

73

Citations

22

References

2013

Year

Michaël Vouche, Laura Kulik, Rohi Atassi, Khairuddin Memon, Ryan Hickey, Daniel Ganger, Frank H. Miller, Vahid Yaghmai, Michaël Abécassis, Talia Baker,
Hepatology

Abstract

The adjunct of Sorafenib did not augment radiological or pathological response to Y90 therapy for HCC. Equivalent significant reduction in enhancement at 1 and 3 months by EASL/mRECIST was noted. Neither EASL nor mRECIST could reliably predict CPN.

References

YearCitations

Page 1